|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPS21 |
Gene summary for MRPS21 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPS21 | Gene ID | 54460 |
| Gene name | mitochondrial ribosomal protein S21 | |
| Gene Alias | MDS016 | |
| Cytomap | 1q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | P82921 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54460 | MRPS21 | GSM4909281 | Human | Breast | IDC | 1.27e-21 | 5.40e-01 | 0.21 |
| 54460 | MRPS21 | GSM4909282 | Human | Breast | IDC | 2.00e-09 | 3.79e-01 | -0.0288 |
| 54460 | MRPS21 | GSM4909285 | Human | Breast | IDC | 1.21e-09 | 4.31e-01 | 0.21 |
| 54460 | MRPS21 | GSM4909287 | Human | Breast | IDC | 2.35e-08 | 3.59e-01 | 0.2057 |
| 54460 | MRPS21 | GSM4909288 | Human | Breast | IDC | 1.11e-04 | 2.03e-01 | 0.0988 |
| 54460 | MRPS21 | GSM4909290 | Human | Breast | IDC | 3.89e-05 | 3.82e-01 | 0.2096 |
| 54460 | MRPS21 | GSM4909293 | Human | Breast | IDC | 2.68e-27 | 5.79e-01 | 0.1581 |
| 54460 | MRPS21 | GSM4909294 | Human | Breast | IDC | 4.76e-11 | -1.18e-01 | 0.2022 |
| 54460 | MRPS21 | GSM4909296 | Human | Breast | IDC | 8.81e-19 | 1.17e-01 | 0.1524 |
| 54460 | MRPS21 | GSM4909297 | Human | Breast | IDC | 1.53e-24 | -9.59e-02 | 0.1517 |
| 54460 | MRPS21 | GSM4909301 | Human | Breast | IDC | 1.77e-138 | 1.18e+00 | 0.1577 |
| 54460 | MRPS21 | GSM4909302 | Human | Breast | IDC | 1.79e-07 | 2.57e-01 | 0.1545 |
| 54460 | MRPS21 | GSM4909306 | Human | Breast | IDC | 1.06e-04 | 3.26e-01 | 0.1564 |
| 54460 | MRPS21 | GSM4909307 | Human | Breast | IDC | 8.29e-12 | 3.64e-01 | 0.1569 |
| 54460 | MRPS21 | GSM4909308 | Human | Breast | IDC | 1.05e-02 | 2.88e-01 | 0.158 |
| 54460 | MRPS21 | GSM4909309 | Human | Breast | IDC | 1.16e-05 | 1.53e-01 | 0.0483 |
| 54460 | MRPS21 | GSM4909311 | Human | Breast | IDC | 5.13e-52 | -3.20e-01 | 0.1534 |
| 54460 | MRPS21 | GSM4909312 | Human | Breast | IDC | 2.38e-24 | -2.69e-01 | 0.1552 |
| 54460 | MRPS21 | GSM4909313 | Human | Breast | IDC | 2.23e-08 | 2.51e-01 | 0.0391 |
| 54460 | MRPS21 | GSM4909319 | Human | Breast | IDC | 4.80e-57 | -4.73e-01 | 0.1563 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00325432 | Breast | IDC | mitochondrial translation | 13/1434 | 76/18723 | 4.81e-03 | 3.67e-02 | 13 |
| GO:003254311 | Breast | DCIS | mitochondrial translation | 13/1390 | 76/18723 | 3.70e-03 | 2.99e-02 | 13 |
| GO:00325435 | Esophagus | HGIN | mitochondrial translation | 23/2587 | 76/18723 | 1.61e-04 | 3.16e-03 | 23 |
| GO:01400534 | Esophagus | HGIN | mitochondrial gene expression | 27/2587 | 108/18723 | 1.34e-03 | 1.57e-02 | 27 |
| GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
| GO:003254314 | Esophagus | ESCC | mitochondrial translation | 68/8552 | 76/18723 | 1.02e-15 | 6.86e-14 | 68 |
| GO:0032543 | Liver | Cirrhotic | mitochondrial translation | 40/4634 | 76/18723 | 1.61e-07 | 4.29e-06 | 40 |
| GO:0140053 | Liver | Cirrhotic | mitochondrial gene expression | 49/4634 | 108/18723 | 2.35e-06 | 4.31e-05 | 49 |
| GO:01400531 | Liver | HCC | mitochondrial gene expression | 82/7958 | 108/18723 | 1.49e-12 | 7.20e-11 | 82 |
| GO:00325431 | Liver | HCC | mitochondrial translation | 62/7958 | 76/18723 | 2.95e-12 | 1.34e-10 | 62 |
| GO:01400533 | Oral cavity | OSCC | mitochondrial gene expression | 78/7305 | 108/18723 | 2.37e-12 | 9.86e-11 | 78 |
| GO:00325434 | Oral cavity | OSCC | mitochondrial translation | 59/7305 | 76/18723 | 7.21e-12 | 2.70e-10 | 59 |
| GO:003254313 | Oral cavity | LP | mitochondrial translation | 43/4623 | 76/18723 | 2.85e-09 | 1.26e-07 | 43 |
| GO:014005312 | Oral cavity | LP | mitochondrial gene expression | 53/4623 | 108/18723 | 3.54e-08 | 1.27e-06 | 53 |
| GO:00325433 | Prostate | BPH | mitochondrial translation | 23/3107 | 76/18723 | 2.21e-03 | 1.22e-02 | 23 |
| GO:01400532 | Prostate | BPH | mitochondrial gene expression | 29/3107 | 108/18723 | 4.68e-03 | 2.25e-02 | 29 |
| GO:003254312 | Prostate | Tumor | mitochondrial translation | 24/3246 | 76/18723 | 1.73e-03 | 1.03e-02 | 24 |
| GO:014005311 | Prostate | Tumor | mitochondrial gene expression | 31/3246 | 108/18723 | 2.31e-03 | 1.30e-02 | 31 |
| GO:00325436 | Skin | cSCC | mitochondrial translation | 47/4864 | 76/18723 | 4.70e-11 | 2.22e-09 | 47 |
| GO:01400535 | Skin | cSCC | mitochondrial gene expression | 56/4864 | 108/18723 | 8.06e-09 | 2.56e-07 | 56 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa03010 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa030101 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa030102 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa030103 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa030104 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa030105 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa0301026 | Endometrium | AEH | Ribosome | 89/1197 | 167/8465 | 1.88e-33 | 6.09e-31 | 4.46e-31 | 89 |
| hsa03010112 | Endometrium | AEH | Ribosome | 89/1197 | 167/8465 | 1.88e-33 | 6.09e-31 | 4.46e-31 | 89 |
| hsa0301027 | Endometrium | EEC | Ribosome | 89/1237 | 167/8465 | 2.55e-32 | 8.39e-30 | 6.26e-30 | 89 |
| hsa0301036 | Endometrium | EEC | Ribosome | 89/1237 | 167/8465 | 2.55e-32 | 8.39e-30 | 6.26e-30 | 89 |
| hsa0301039 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
| hsa03010115 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
| hsa03010211 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa03010310 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa0301022 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301032 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPS21 | SNV | Missense_Mutation | c.128N>A | p.Arg43Gln | p.R43Q | protein_coding | tolerated(0.21) | benign(0.041) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MRPS21 | SNV | Missense_Mutation | rs782778925 | c.155G>A | p.Arg52Gln | p.R52Q | protein_coding | tolerated(0.05) | benign(0.041) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| MRPS21 | SNV | Missense_Mutation | novel | c.26N>A | p.Ala9Asp | p.A9D | protein_coding | tolerated(0.06) | benign(0.244) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MRPS21 | SNV | Missense_Mutation | c.242C>T | p.Ala81Val | p.A81V | protein_coding | tolerated(0.45) | benign(0.003) | TCGA-AG-3894-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| MRPS21 | SNV | Missense_Mutation | novel | c.20N>A | p.Phe7Tyr | p.F7Y | protein_coding | deleterious(0.05) | probably_damaging(0.923) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MRPS21 | SNV | Missense_Mutation | rs782225927 | c.209N>A | p.Arg70His | p.R70H | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| MRPS21 | SNV | Missense_Mutation | rs371854457 | c.182N>A | p.Arg61Gln | p.R61Q | protein_coding | tolerated(0.14) | benign(0.01) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
| MRPS21 | SNV | Missense_Mutation | rs781892346 | c.151C>T | p.Arg51Trp | p.R51W | protein_coding | tolerated(0.11) | benign(0.014) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response | |
| MRPS21 | SNV | Missense_Mutation | c.28N>T | p.Arg10Trp | p.R10W | protein_coding | deleterious(0.01) | benign(0.191) | TCGA-CC-A7IK-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | ||
| MRPS21 | SNV | Missense_Mutation | c.185G>T | p.Arg62Leu | p.R62L | protein_coding | deleterious(0.05) | possibly_damaging(0.626) | TCGA-50-5049-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |